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Abstract
Introduction Overexpression of the apoptosis-related protein
clusterin is associated with breast cancer development and
tumor progression. We describe the use of clusterin-specific
antisense oligonucleotides and antibodies to sensitize breast
carcinoma cells to anticancer drugs routinely used in breast
cancer therapy.
Methods MCF-7 and MDA-MB-231 cells were treated with the
oligonucleotide or antibody, chemotherapeutic agents
(doxorubicin or paclitaxel), tamoxifen, or with combinations of
these.
Results Treatments that include antisense clusterin
oligonucleotide or antibody to clusterin have been shown to
reduce the number of viable cells more effectively than treatment
with the drugs alone. We also demonstrate that dexamethasone
pretreatment of breast cancer cell lines inhibits chemotherapy-
induced cytotoxicity and is associated with the transcriptional
induction of clusterin. However, anticlusterin treatment
increases chemotherapy-induced cytotoxicity, even in the
presence of glucocorticoids, suggesting a possible role for
these proteins in glucocorticoid-mediated survival.
Conclusion These data suggest that combined treatment with
antibodies to clusterin or antisense clusterin
oligodeoxynucleotides and paclitaxel, doxorubicin, or tamoxifen
could be a novel and attractive strategy to inhibit the
progression of breast carcinoma by regulation of the clusterin
function. Moreover, glucocorticoid activation in breast cancer
cells regulates survival signaling by the direct transactivation of
genes like clusterin which encode proteins that decrease
susceptibility to apoptosis. Given the widespread clinical
administration of dexamethasone before chemotherapy,
understanding glucocorticoid-induced survival mechanisms is
essential for achieving optimal therapeutic responses.
Introduction
Breast cancer is the most frequently diagnosed cancer in
women today, and its incidence has steadily increased in
recent decades. Resistance to anticancer chemotherapeutic
drugs remains a major obstacle in cancer chemotherapy, and
novel therapeutic strategies that target the molecular basis of
chemoresistance are required. In this sense, the response of
cytotoxic drugs is modulated by pro- and antiapoptotic pro-
teins, and defects in apoptosis pathways or the activation of
antiapoptotic mechanisms may confer resistance to cytotoxic
drug treatment. In fact, the downregulation of the CD-95
receptor/ligand system, deficient expression of caspase family
members, or the overexpression of antiapoptotic bcl-2 protein
have all been observed in drug-resistant tumors [1]. The clus-
terin protein is an inhibitor of apoptosis with a cytoprotective
function [2] and thus represents a promising target for molec-
IgG = immunoglobulin G; ODN = oligodeoxynucleotide; PCR = polymerase chain reaction; RT-PCR = reverse transcription-polymerase chain reac-
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ular intervention strategies such as antisense therapy
designed to inhibit its expression [3]. The overexpression of
exogenous clusterin has been shown to result in resistance to
paclitaxel [4], doxorubicin [5], cisplatin [6], and radiation ther-
apy [7]. In contrast, decreased clusterin expression by anti-
sense or small interfering RNA (siRNA) expression enhances
the chemosensitivities of various cell lines [8-11], suggesting
that clusterin expression is a prominent resistance factor in
cancer cells.
On the other hand, glucocorticoids (such as dexamethasone)
are routinely used in the clinical application of chemotherapy
to prevent adverse effects. A previous study reported the
inhibitory action of glucocorticoids on chemotherapy-induced
apoptosis, which also raises a clinically relevant question as to
whether the pretreatment with glucocorticoids might interfere
with the therapeutic efficacy of chemotherapy [12].
Glucocorticoids play a major role in attenuation of the inflam-
matory response. These steroid hormones are able to induce
apoptosis in cells of the hematopoietic system such as the
monocytes, macrophages, and T lymphocytes that are
involved in the inflammation reaction. In contrast, it has
recently been discovered that in glandular cells such as the
mammary gland epithelia, hepatocytes, and ovarian follicular
cells and in fibroblasts, glucocorticoids protect against the
apoptotic signals evoked by cytokines, cAMP, tumor suppres-
sors, and death genes. It is well known that the antiapoptotic
effect of glucocorticoids is exerted by the modulation of sur-
vival genes such as Bcl-2, Bcl-x(L), and nuclear factor-kappa
B in a cell type-specific manner [13]. We hypothesize that
clusterin may be one of these genes responsible for the antia-
poptotic effect of glucocorticoids.
Increased expression of the clusterin gene has been observed
in breast cancer cells and has been associated with the devel-
opment and progression of these tumors [14]. Moreover, clus-
terin overexpression has been shown to be associated with
the anti-HER-2 antibody trastuzumab (Herceptin) treatment
resistance through the inhibition of apoptosis [15]. To explore
the potential of the clusterin inhibition approach in breast can-
cer therapy, the cytotoxic interaction between antisense clus-
terin oligonucleotide or anticlusterin antibody and the drugs
commonly used in breast cancer treatment such as dexameth-
asone, doxorubicin, paclitaxel, and tamoxifen were analyzed in
vitro using the breast carcinoma cell lines MCF-7 and MDA-
MB-231.
Materials and methods
Cell lines
Estrogen-independent MDA-MB-231 and estrogen-depend-
ent MCF-7 breast cancer cell lines were obtained from the
American Type Culture Collection (Manassas, VA, USA). They
were maintained in RPMI 1640 (Sigma-Aldrich, St. Louis, MO,
USA) supplemented with 10% fetal bovine serum.
Anticancer drugs
Dexamethasone, tamoxifen, doxorubicin, and paclitaxel were
obtained from Sigma-Aldrich. Stock solutions were prepared
with phosphate-buffered saline to the required concentrations
before each in vitro experiment.
Total RNA isolation and reverse transcription-
polymerase chain reaction
Isolation of total RNA was performed by the guanidium isothi-
ocyanate method as originally described by Chomczynski and
Sacchi [16]. In brief, 1 × 107 cells or 100-mg tissue fragments
were first resuspended in 500 μL of a guanidium isothiocy-
anate solution. After phenol/chloroform extraction, 400 μL of
the upper aquatic phase was transferred into a new tube, and
RNA was precipitated with 2.5 volumes of absolute ethanol.
The purity and integrity of the isolated RNA were determined
by spectrophotometry and denaturing formaldehyde agarose
gel electrophoresis, respectively. If necessary, isolated total
RNA was treated with 2 units of RNase-free DNase I (Roche
Molecular Biochemical, Mannheim, Germany) for 2 hours at
37°C to remove all possible genomic DNA contamination.
Reverse transcription into cDNA was performed using a com-
mercial kit (Roche Molecular Biochemical) in accordance with
the manufacturer's instructions. Polymerase chain reaction
(PCR) was performed using the following primers for detec-
tion of clusterin and α-actin signals, respectively: clusterin: 5'-
GGCGACGATGACCGGACTGT-3' and 5'-GGGACCGT-
CACAGTGATGGG-3';  β-actin: 5'-GGCATCGTGAT-
GGACTCCG-3' and 5'-GCTGGAAGGTGGACAGCGA-3'.
Using reverse-transcribed cDNA, all PCRs were performed in
accordance with the following protocol: 5 minutes of denatur-
ation at 95°C, 30 cycles of a 30-second denaturation step at
95°C, 1-minute annealing at 64°C, 30-second elongation at
72°C, and a final elongation step for 5 minutes at 72°C. PCR
was performed on a GeneAmp 2400 thermal cycler (Perk-
inElmer Inc., Waltham, MA, USA) using 0.5 units of Taq
polymerase (Roche) per reaction. The PCR products were
analyzed in a 1.5% TAE (Tris Acetate EDTA)-buffered agarose
gel.
Changes in clusterin expression
To determine whether tamoxifen and dexamethasone altered
clusterin expression, the cells were treated with charcoal-
stripped serum (Merck & Co., Inc., Whitehouse Station, NJ,
USA) to remove steroids. All drugs were assayed at concen-
trations of 10-7 and 10-8 M. Clusterin levels were determined
at 4, 8, 24, 48, 96, 120, and 144 hours.
Treatment of cells with oligonucleotides
The phosphorothioate oligodeoxynucleotides (ODNs) used in
this study were provided by Roche Molecular Biochemical.
The sequence of oligonucleotides to clusterin, corresponding
to the mouse clusterin translation initiation site, was 5'-
GCACAGCAGGAGAATCTTCAT-3'. A two-base clusterinAvailable online http://breast-cancer-research.com/content/9/6/R86
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mismatch ODN (5'-GCACAGCAGGAGGATATTCAT-3') was
used as a control. These sequences of oligonucleotides have
been previously shown to reduce levels of clusterin and to sig-
nificantly delay disease progression in prostate and bladder
tumor models in animals [8,17]. Furthermore, a second gener-
ation of this antisense oligonucleotide has been produced for
use in humans (OGX-011, a 2' methoxyethyl modified phos-
phorothioate antisense oligonucleotide; OncoGenex Technol-
ogies Inc., Vancouver, BC, Canada).
In vitro-cultured cells were treated with various concentrations
of ODN (ranging from 10 to 500 nM) after a preincubation for
20 minutes with 1.5 μg/mL lipofectin (Life Technologies, Glas-
gow, UK) to enhance transfection in serum-free Dulbecco's
modified Eagle's medium (Sigma-Aldrich). Four hours after the
beginning of the incubation, the medium containing ODN and
lipofectin was replaced with standard medium. To determine
the optimal concentrations for reducing mRNA clusterin levels,
concentrations of 10, 100, 500, and 1,000 nM were assayed,
and a concentration of 100 nM was found to produce maximal
reduction in clusterin mRNA levels. At none of the concentra-
tions employed were clusterin levels affected by mismatch
control oligonucleotides.
Dose-response curves for chemotherapeutic agents were also
produced to determine the appropriate dosages. Thus, breast
tumor cells were incubated once daily for 2 days with anti-
sense oligonucleotides at a concentration of 100 nM and then
incubated with chemotherapeutic agents for 1 day (at 10-7 and
10-8 M).
Antibody treatment of cells
Goat antilipoprotein J polyclonal was provided by Chemicon
International (Temecula, CA, USA). Taking into account a pre-
vious report, concentrations of 20, 30, and 40 μg/mL were
assayed [18]. A dose of 30 μg/mL was found to have the max-
imal effect on breast carcinoma cells. In assays with chemo-
therapeutic agents, the cells were incubated for 1 day with the
anticlusterin antibody and then treated for a further day with
the chemotherapeutic agent.
Determination of cell viability
The cells were distributed at 50,000 cells per well in 12-well
plates and treated with oligonucleotides and the anticancer
drugs, and floating and adherent cells were recovered. The
number of viable cells was determined by trypan blue exclu-
sion analysis.
TUNEL assay
After the period of incubation, the cells were immediately fixed
by adding 37% formaldehyde and incubating them at room
temperature for 30 minutes. The fixed cells were then allowed
to dry overnight. To score for apoptosis, a TUNEL (terminal
deoxynucleotidyl transferase-mediated dUTP-biotin nick end-
labeling) technique was used to detect apoptotic cells in
breast cancer cell lines using the Roche in situ Apoptosis
Detection System in accordance with the manufacturer's pro-
tocol. The percentage of positively stained cells per total
number of cells per high-power field in five random fields was
counted and averaged.
Statistical analysis
One-way analysis of variance was used to compare means.
The level of statistical significance was set at a p value of less
than 0.05, and all statistical calculations were carried out
using SPSS.14 software (SPSS Inc., Chicago, IL, USA).
Results
Enhanced expression of clusterin after treatments with 
dexamethasone, tamoxifen, paclitaxel, and doxorubicin
The MCF-7 cells treated with 1 × 10-7 M dexamethasone (a
pharmacologically achievable dose) expressed maximal levels
of clusterin by reverse transcription (RT)-PCR as early as 4
hours after induction, and these high levels were maintained
even at 4 days after treatment (Figure 1). After this point, the
level began to decrease (data not shown). In the MDA-MB-
231 cell line, which expresses clusterin at high levels in basal
conditions, no significant changes were observed in clusterin
expression (data not shown).
RT-PCR analysis was also used to determine the effects of
chemotherapeutic agents and tamoxifen on clusterin RNA
expression in breast cancer cell lines. As shown in Figure 1,
clusterin RNA induction increased in the MCF-7 cell line for
both treatments. Time course experiments in breast cancer
cells demonstrated that clusterin RNA upregulation peaked as
early as 4 to 8 hours after treatment. Again, in the MDA-MB-
231 cell line, no significant changes were observed.
Effects of antisense clusterin on clusterin mRNA and 
protein expression
RT-PCR analysis was used to determine the effect of treat-
ment with antisense clusterin ODN on clusterin RNA expres-
sion in breast carcinoma cells. As shown in Figure 2, treatment
of breast tumor cells with 100 or 500 nM antisense clusterin
ODN decreased clusterin compared with cells treated with
mismatch control ODN. Western blotting confirmed the
changes in clusterin protein expression (data not shown).
We determined the effect of antisense clusterin treatment in
both cell lines. In the MDA-MB-231 cell line, which expresses
high levels of clusterin in basal conditions, antisense clusterin
at concentrations of 100 and 500 nM produced a very signifi-
cant decrease in cell viability. In the MCF-7 cell line, which
expresses clusterin at lower levels, this difference was statisti-
cally significant (Figure 3). The anticlusterin antibody at a con-
centration of 30 μg/mL also produced significant results for
the percentage of cytotoxicity compared with that produced
with a nonimmune immunoglobulin G (IgG) fraction in both cell
lines: MDA-MB-231 (28% ± 4.3% with the anticlusterinBreast Cancer Research    Vol 9 No 6    Redondo et al.
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antibody versus 7% ± 1.5% without the antibody; p = 0.002)
and MCF-7 (69.6% ± 8.3% with the antibody versus 34% ±
6% without the antibody; p = 0.004).
Antisense oligodeoxynucleotide and antibody to 
clusterin increase the cytotoxicity of paclitaxel and 
doxorubicin in MCF-7 and MDA-MB-231
The combination of antisense clusterin ODN or anticlusterin
antibody with the chemotherapeutic drug doxorubicin and
paclitaxel produced a significant additive cytotoxic effect in
both cell lines (Figures 4 and 5). In addition, TUNEL staining
revealed an increased number of apoptotic cells in antisense
clusterin ODN-treated MCF-7 cells compared with treatment
Figure 1
Reverse transcription-polymerase chain reaction analysis showing  upregulation of clusterin in MCF-7 tumor cells after treatment with dex- amethasone (a), chemotherapeutic agent after 1 day of incubation (b),  and tamoxifen (c) Reverse transcription-polymerase chain reaction analysis showing 
upregulation of clusterin in MCF-7 tumor cells after treatment with dex-
amethasone (a), chemotherapeutic agent after 1 day of incubation (b), 
and tamoxifen (c). C, basal expression; D, doxorubicin; MW, molecular 
weight; P, paclitaxel.
Figure 2
Reverse transcription-polymerase chain reaction analysis showing a  strong decrease in clusterin RNA after treatment with antisense oligo- deoxynucleotides to clusterin (ODNclu) in the MDA-MB-231 (a) and  MCF-7 (b) cell lines Reverse transcription-polymerase chain reaction analysis showing a 
strong decrease in clusterin RNA after treatment with antisense oligo-
deoxynucleotides to clusterin (ODNclu) in the MDA-MB-231 (a) and 
MCF-7 (b) cell lines. C, basal expression; MW, molecular weight; 
ODNc, control oligonucleotide.
Figure 3
Effects of antisense clusterin oligonucleotide (ODNclu) on cytotoxicity  of breast tumor cell lines Effects of antisense clusterin oligonucleotide (ODNclu) on cytotoxicity 
of breast tumor cell lines. Cells were treated daily with 100 or 500 nM 
antisense ODNclu or clusterin mismatch control ODN (ODNc) for 2 
days. Cell viability was determined by trypan blue exclusion test. Each 
data point represents the mean percentages of at least three independ-
ent experiments ± standard error of the mean. *p < 0.05; **p < 0.01.Available online http://breast-cancer-research.com/content/9/6/R86
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with mismatch control oligonucleotides plus chemotherapy
(61.3% ± 4% versus 37.6% ± 1.4% for paclitaxel, p < 0.01,
and 79.6% ± 2.6% versus 35% ± 12% for doxorubicin, p <
0.05).
Anticlusterin treatment increases the efficacy of 
tamoxifen
MCF-7 cells were treated with tamoxifen (10-7 M) for 1 day and
then incubated with antisense oligonucleotides (2 days) or
anticlusterin antibody (1 day), after which they were treated
with tamoxifen (10-7 M) for 1 day. Again, a significant additive
cytotoxic effect was obtained with the combined treatment
(Figure 6). Thus, tamoxifen combined with clusterin antibody
produced a significant effect on cytotoxicity (57.3% ± 1.7%
versus 31.6% ± 5.7%; p < 0.01). According to the TUNEL
assay, clusterin oligonucleotides also enhanced apoptosis
induced by tamoxifen (72.7% ± 2.4% versus 46.7% ± 4.7%;
p < 0.01) or by tamoxifen plus paclitaxel (80% ± 2.3% versus
59.6% ± 3.1%; p < 0.01).
Figure 4
Effects of combined treatment with antisense clusterin oligonucleotide  (ODNclu) and paclitaxel or doxorubicin on cytotoxicity of the MDA-MB- 231 (a) and MCF-7 (b) cell lines Effects of combined treatment with antisense clusterin oligonucleotide 
(ODNclu) and paclitaxel or doxorubicin on cytotoxicity of the MDA-MB-
231 (a) and MCF-7 (b) cell lines. Cells were treated daily with 100 nM 
antisense ODNclu or clusterin mismatch control ODN (ODNc) for 2 
days. After ODN treatment, the medium was replaced with medium 
containing 10-7 and 10-8 M paclitaxel or doxorubicin. Cell viability was 
determined by trypan blue exclusion test. Each data point represents 
the mean percentages of at least three independent experiments ± 
standard error of the mean. D, doxorubicin; P, paclitaxel. *p < 0.05; **p 
< 0.01; ***p < 0.001.
Figure 5
Effects of combined treatment with anticlusterin antibody and paclitaxel  or doxorubicin on cytotoxicity of the MDA-MB-231 and MCF-7 cell lines Effects of combined treatment with anticlusterin antibody and paclitaxel 
or doxorubicin on cytotoxicity of the MDA-MB-231 and MCF-7 cell 
lines. Cells were treated with the antibody for 1 day (30 μg/mL). After 
antibody treatment, the medium was replaced in some wells with 
medium containing 10-7 M paclitaxel or doxorubicin for 1 day. Cell via-
bility was determined by trypan blue exclusion test. Each data point 
represents the mean percentages of at least three independent experi-
ments ± standard error of the mean. **p < 0.01. Differences were cal-
culated comparing the combined treatment with anticlusterin antibody 
or chemotherapeutic agent alone. D, doxorubicin; P, paclitaxel.
Figure 6
Effects of combined treatment with antisense clusterin oligonucleotide  (ODNclu) (at 100 and 500 nM) and tamoxifen (10-7 M) on cytotoxicity  of the MCF-7 cell line Effects of combined treatment with antisense clusterin oligonucleotide 
(ODNclu) (at 100 and 500 nM) and tamoxifen (10-7 M) on cytotoxicity 
of the MCF-7 cell line. The same treatment schedule described in figure 
3 was followed. **p < 0.01; ***p < 0.001. ODNc, control 
oligonucleotide.Breast Cancer Research    Vol 9 No 6    Redondo et al.
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Dexamethasone pretreatment significantly decreases 
the efficacy of doxorubicin and paclitaxel
Dexamethasone pretreatment of breast cancer cell lines is
associated with the transcriptional induction of clusterin. As
expected, treatment with antisense oligonucleotides to clus-
terin represses the effect of dexamethasone on clusterin. By
the TUNEL method, dexamethasone did not present
statistically significant differences in the percentage of apop-
tosis with respect to control with medium alone after 1 day of
incubation in the MCF-7 cell line (10% ± 5% versus 11.6% ±
5.7%, respectively). However, dexamethasone treatment
clearly inhibits chemotherapy-induced cytotoxicity (Figure 7a).
These findings indicate that the combination of dexametha-
sone with conventional chemotherapeutic agents may result in
antagonistic antitumor effects. However, antisense oligonucle-
otides to clusterin increase chemotherapy-induced cytotoxic-
ity, even in the presence of glucocorticoid treatment,
suggesting a possible role for these proteins in glucocorticoid-
mediated survival (Figure 7b). Evaluation of in situ apoptosis
revealed similar results. Thus, in the treatment with taxol plus
dexamethasone, the percentage of apoptosis with control oli-
gonucleotides was 23.3% ± 6.6% versus 46.3% ± 4.6% with
antisense oligonucleotides to clusterin.
Discussion
Although clusterin expression in normal breast epithelial cells
is low or absent, it is very high in breast cancer cells during
carcinogenesis and metastatic progression [14]. In prostate
cancer, the accumulated evidence strongly suggests that
clusterin overexpression protects cancer cells from apoptotic
cell death induced by several therapies, including hormone
and cytotoxic therapy, thereby accelerating progression to
androgen independence and conferring chemoresistance
[4,8,19]. The combined use of antisense oligonucleotides with
cytotoxic chemotherapy has been shown to produce more
potent antineoplastic effects [8,19,20].
The present study confirms in the estrogen receptor-positive
breast cancer cell line MCF-7 that clusterin levels increase
after treatment with tamoxifen and dexamethasone. Previous
studies have reported increased clusterin expression after
treatment with toremifene [21] and tamoxifen [22]. We also
evaluated the effect of cytotoxic treatment on the level of clus-
terin expression in breast tumor cell lines because this has
been shown to be highly upregulated in various tissues under-
going apoptotic cell death [23,24]. As expected, clusterin
expression in MCF-7 cells was found to increase considerably
after cytotoxic treatment, suggesting that clusterin upregula-
tion is likely to be an adaptative response that mediates chem-
oresistance. We also investigated the capacity of anticlusterin
treatment to sensitize breast carcinoma cells to chemotherapy
and searched for drug combinations that produce additive
cytotoxicity. Antisense clusterin oligonucleotides or anticlus-
terin antibodies efficiently inhibited clusterin expression in
MCF-7 and MDA-MB-231 cell lines, and this activity was asso-
ciated with a decrease in cell viability. These findings confirm
the cytoprotective function of clusterin in breast carcinoma
cells and suggest that there is a role for anticlusterin therapy
in the treatment of breast carcinomas that mainly express clus-
terin protein [11,14].
In addition, we found that in both cell lines, combinations of
anticlusterin treatment with chemotherapeutic agents or
tamoxifen performed better than the respective single-agent
treatments alone. A sequence control oligonucleotide and
nonimmune IgG fraction did not increase the effect of chemo-
therapy, which suggests that the sensitization of cells to apop-
tosis was due to the specific downregulation of clusterin. A
previous report confirmed the chemosensitivity to paclitaxel in
breast cancer cell lines [11]. In addition, in other tumors, anti-
Figure 7
Effects of dexamethasone pretreatment on chemotherapy-induced  cytotoxicity Effects of dexamethasone pretreatment on chemotherapy-induced 
cytotoxicity. (a) Dexamethasone pretreatment (10-7 M) inhibits chemo-
therapy-induced cytotoxicity in the MCF-7 cell line. (b) However, clus-
terin antisense oligonucleotides (ODNclu) increase chemotherapy-
induced cytotoxicity in the presence of dexamethasone. Cells were 
treated with dexamethasone for 4 hours. After dexamethasone treat-
ment, the medium was replaced in some wells with medium containing 
10-7 M paclitaxel or doxorubicin for 1 day. Cell viability was determined 
by trypan blue exclusion test. Each data point represents the mean per-
centages of at least three independent experiments ± standard error of 
the mean. *p < 0.05; **p < 0.01; ***p < 0.001. Differences between 
treatment with chemotherapeutic agents and treatment with dexameth-
asone alone or dexamethasone plus chemotherapeutic agents are 
shown in (a). D, doxorubicin; ODNc, control oligonucleotide; P, 
paclitaxel.Available online http://breast-cancer-research.com/content/9/6/R86
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clusterin therapy with antisense oligonucleotides
[17,19,25,26] or siRNA [9] has been evaluated as a potential
therapeutic agent.
Dexamethasone, a synthetic steroid, is routinely given to
women just before they receive chemotherapy with either
paclitaxel or doxorubicin, two drugs commonly used to treat
breast cancer. Recent findings show that corticoids could pro-
tect against chemotherapy-induced apoptosis [12]. Our
results show that clusterin expression is increased by dexam-
ethasone treatment. About 4 hours after hormone application,
a large increase in clusterin mRNA levels was detectable and
was maintained at this high level even at 96 hours after treat-
ment (Figure 1). After this point, the level began to decrease.
A similar response by clusterin after treatment with glucocorti-
coids was obtained on hemangioma in vitro [27]. These
results, together with the facts that dexamethasone inhibits
chemotherapy-induced cytotoxicity and that antisense oligo-
nucleotides to clusterin increase chemotherapy-induced
cytotoxicity, clearly show that dexamethasone modulates the
expression of clusterin. This effect is in agreement with the
known anti-inflammatory properties of dexamethasone in
upregulating the expression of other complement inhibitors
[28].
Conclusion
We suggest that glucocorticoids may influence breast cancer
behavior via the upregulation of clusterin, which might play a
major role in the effects of dexamethasone, protecting breast
cancer cells from the effects of both paclitaxel and
doxorubicin. Blocking clusterin, on the other hand, reverses
the drug's unwanted effects on cancer cell survival. In addition,
our studies have firmly established a role for clusterin as a cell
survival gene that is increased after tamoxifen therapy and
chemotherapy to inhibit tumor cell death. The inhibition of clus-
terin, using antisense oligonucleotides and antibodies,
enhances the cytotoxic effects of chemotherapy agents,
including paclitaxel and doxorubicin.
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